MMedication Read More Why Revolution Medicines May Be Big Pharma’s Next Takeover TargetAugust 12, 2026 Quick Read RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus…
HHealthcare Read More Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform TechJune 10, 2026 Quick Read Merck’s Keytruda posted $8 billion in Q1 sales, while Summit’s ivonescimab faces binary risk ahead of…
HHealthcare Read More Global drug makers face pricing pressure as China targets affordable healthcareApril 8, 2026 Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…
HHealthcare Read More Merck’s Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?December 9, 2025 Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning…
MMedication Read More Some Georgians could soon be paying double for their medications – WSB-TV Channel 2September 30, 2025 ATLANTA — In just a matter of days, President Donald Trump’s pharmaceutical tariff policy will go into effect,…